4582 — SymBio Pharmaceuticals Cashflow Statement
0.000.00%
- ¥5bn
- ¥4bn
- ¥2bn
Annual cashflow statement for SymBio Pharmaceuticals, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4,086 | 1,001 | 2,106 | -1,195 | -3,807 |
| Depreciation | |||||
| Non-Cash Items | -353 | 315 | -439 | 432 | 54.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 253 | -1,270 | -138 | 472 | 336 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4,122 | 140 | 1,628 | -195 | -3,417 |
| Capital Expenditures | -149 | -63.8 | -47.6 | -233 | -46.9 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -11.4 | -7.01 | 0.431 | -144 | 42.9 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -160 | -70.8 | -47.1 | -377 | -3.96 |
| Financing Cash Flow Items | -16.8 | -4 | -32.1 | -11.5 | -19.7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 4,222 | -71.9 | 628 | 680 | 708 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -62.2 | 11.5 | 2,422 | 234 | -2,553 |